Medpace Holdings, Inc. (MEDP) Share Buybacks
The buybacks for Medpace Holdings, Inc. (MEDP) is $917.39 Million with a year-over-year change of +440.06%. Share buybacks (stock repurchases) represent cash spent by the company to buy back its own shares in the open market, reducing shares outstanding and returning capital to shareholders.
MEDP Buybacks Chart
Current Buybacks
$917.39M
$917.39 Million
Year-over-Year Change
+440.06%
vs. $169.87M prior year
Historical Data
7
Years of data available
Annual Buybacks History
| Year | Buybacks | YoY Change | % Change |
|---|---|---|---|
| 2025 | $917.39M | +$747.52M | +440.06% |
| 2024 | $169.87M | +$25.85M | +17.95% |
| 2023 | $144.02M | $-703.83M | -83.01% |
| 2022 | $847.85M | +$785.75M | +1265.38% |
| 2021 | $62.10M | $-36.18M | -36.81% |
| 2020 | $98.27M | $-57.31M | -36.84% |
| 2017 | $155.58M | — | — |
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle